Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes following MRD relapse in AML patients monitored by droplet digital PCR

View Full Paper
Ask AI
Bookmark
Share

Authors

SNStephen H. NantelAKAly KarsanSYSean D. Young

Discussion

Loading...

Member takes

Overview

Observational analysis reports improved clinical outcomes in AML patients monitored for MRD relapse, indicating benefits of azacitidine.

Key Points

  • Overall survival rates were better for patients with MRD relapse after chemotherapy, highlighting the significance of early intervention.
  • Kaplan-Meier survival estimator indicated a notable difference in overall survival based on MRD relapse criteria defined by the European Leukemia Network.
  • Patients receiving azacitidine for MRD relapse had a substantial response rate, suggesting effective pre-emptive treatment options.
  • The study emphasizes the role of your monitoring in managing hematologic malignancies and guiding treatment decisions.

Cite This Study

Nantel et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0aehttps://doi.org/10.1182/blood-2025-1738
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025
  2. 2A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  3. 3Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025
  4. 4Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group2025
  5. 5Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations